NHIF approves two new medications and expands access to treatment with nine specialized commissions

The Supervisory Board of the NHIF has approved two new medicinal products for treatment under protocol, as well as the establishment of nine new commissions. These will expand patient access to therapies in outpatient care.

Among the newly approved medications is Inebilizumab, intended for monotherapy in adult patients with neuromyelitis optica spectrum disorders (Devic’s disease) who are AQP4-IgG seropositive. The second product—Givosiran—is included for the treatment of acute hepatic porphyria (AHP) in patients aged 12 and older.

A specialized commission is also being established at UMBAL Pulmed – Plovdiv for the treatment of systemic lupus erythematosus with disease-modifying drugs. The new rules simplify administrative procedures for therapy changes, eliminating the need for NHIF expertise when adjusting dosages or switching INNs.

Additionally, the network of commissions for the treatment of the following is being expanded:

• Crohn’s disease and ulcerative colitis in patients over 18 years of age – in Plovdiv (Pulmed) and Pleven (Heart and Brain);
• Chronic viral hepatitis B – in Burgas, Pleven (Heart and Brain), and UMBAL St. Marina – Pleven;
• Chronic viral hepatitis C – in the same medical facilities, with the clarification that medications with INN Sofosbuvir, Ledipasvir, Elbasvir, and Grazoprevir are excluded from treatment due to their removal from the Positive Drug List.

All decisions of the Supervisory Board can be viewed here.